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Quinazoline is the main six-membered heterocyclic ring system reported for their 
biological activities, compounds with multiple pharmacophores, which bring together 
knowledge of a target with understanding of the molecule types that might interact with the 
target family. Robust, versatile and scalable chemistry must be employed to accomplish the 
task. This characteristic feature of quinazoline would make a good template for a lead 
generation library. The current review article focuses on biological actions done for various 
targets along with the brief description of the targets. 
 
 
Medicinal chemistry is concerned with discovery, development, synthesis in laboratory 
and identification of physical and chemical methods. Here most of activity is directed to new 
natural or synthetic organic compounds. Inorganic compounds continue to be important in 
therapy that is trace elements in nutritional therapy, antacids & radiopharmaceuticals. 
Development of organic compounds has now new synthetic methods that includes exciting new 
field of biotechnology using cell’s biochemistry to synthesize new compounds. Techniques 
ranging from recombinant DNA and site directed mutagenesis to fusion of cell lines have 
greatly broadened possibilities for new entities that treat the disease. By help of medicinal 
chemistry now pharmacist dispenses modified human insulin that provide more convenient 
dosing schedules, cell stimulating factors that  have changed the dosing regimens for 
chemotherapy, humanized monoclonal antibodies that target specific tissues and fused 
receptors that intercept immune cell generated cytokines. For understanding principles of 
medicinal chemistry, it is necessary to consider physiochemical properties, used to develop new 
pharmacologically active constituents and their mechanism of action. Hundreds of thousands of 
new organic chemicals are prepared annually throughout world; many of them are entered to 
pharmacological screening for determining their biological activity. This random screening 
process has been inefficient, but it has resulted in identification of new lead compounds whose 
structures have been optimized to produce clinical agents. The main aim of medicinal chemist is 
to know the mode of action of drugs at molecular levels.  
 
Heterocyclic chemistry is a chemistry involving the heterocyclic compounds, which has 
atoms of at least two different elements as number of ring. The heterocyclic atoms may be 
inorganic, though the compound contains carbon atoms in the ring. The word hetero means 
“different from carbon and hydrogen”. Many heterocyclic compounds are biosynthesized by 
plants & animals are biologically active. Some heterocyclic compounds are fundamentals of life, 
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like haeme derivatives in blood & chlorophyll essential for photosynthesis in plants. Also the 
DNA & RNA are containing heterocycles.  Dyestuffs of plant origins include indigo blue used 
to dye jeans. Several heterocycles are the basic structure nucleus for nicotine, pyridoxine, 
cocaine, morphine etc. 
 
Quinazoline Fig 1 is a compound made up of two fused six member simple aromatic 
rings- benzene & pyrimidine ring. It is a yellow colored compound, found usually in crystalline 
form. Medicinally it is used as antimalarial agent. It was first prepared by Gabriel in 1903 and 
first isolated from the Chinese plant aseru. The development of research on biological activity of 
quinazoline compounds started when the compound 2-methyl-1,3-aryl-4-quinazoline derivative 
was synthesized. This compound has soporific & sedative action. In last 10 to 15 years of 
research for medicinal has been characterized by significant advances. In 1968 only two 
derivatives were used, soporific & anticonvulsant- methaqualone and diuretic quinathazone. By 
1980, about 50 kinds of derivatives of this class includes medicinal with different biological 
actions like ‘soporific, sedative, tranquilizing, analgesic, anticonvulsant, antitussive, 
myorelexant, antirheumatic, hypotensive, antiallergic, bronchodilating, antidiabetic, 
cholagogue, diuretic, cystatic, antimalarial, spermicidal etc. The search for substances of 
cardiovascular agents begun in quinazoline derivatives after pharmacological screening of 
hypotensive activity of quinazoline that have a glycine amide or β-alanine amide residue in 3rd 
position. But unfortunately due to volume & density of general material on quinazoline 
derivatives, more specific problem of investigation of cardiovascular agents not has been 
successfully reflected in some reviews. 
 
 
 
 
 
 
 
Fig 1 Quinazoline 
 
 
Prazosin 
Prazosin (Shen, 2008) is chemically 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-
amine Fig 2. It is a sympatholytic drug used to treat high blood pressure. It belongs to the class 
of alpha-adrenergic blockers, which lower blood pressure by relaxing blood vessels. 
Specifically, prazosin is selective for the alpha-1 receptors on vascular smooth muscle. These 
receptors are responsible for the vasoconstrictive action of norepinephrine, which would 
normally raise blood pressure. By blocking these receptors, prazosin reduces blood pressure. It 
is also known as Minipress, Vasoflex , Pressin and Hypovase. 
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Fig 2 Prazosin 
 
Gefitinib 
Gefitinib Fig 3 also known as Iressa marketed by AstraZeneca and Teva. It is a drug used in the 
treatment of certain types of cancer. Gefitinib is an EGFR inhibitor (epidermal growth factor 
receptor) which interrupts signaling through the epidermal growth factor receptor in target 
cells. Gefitinib has yet to be proven to be effective in other cancers, there is potential for its use 
in the treatment of other cancers where EGFR over expression is involved. Applications to 
expand its label as a first line treatment in patients harbouring EGFR mutations is currently in 
process based on the latest scientific evidence. Chemically it is N-(3-chloro-4-fluoro-phenyl)-7-
methoxy-6-(3-morpholin-4-ylpropoxy) quinazolin-4-amine (Pao et al., 2004) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3 Gefitinib 
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Erlotinib 
The trade name of Erlotinib Fig 4 is Tarceva and its chemically known as N-(3-ethynylphenyl)-
6,7-bis(2-methoxyethoxy)quinazolin-4-amine (Raymond et.al., 2000). It is a drug used to treat 
non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a tyrosine 
kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). Erlotinib is an 
EGFR inhibitor. The drug follows Iressa gefitinib, which was the first drug of this type. Erlotinib 
specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is 
highly expressed and occasionally mutated in various forms of cancer. It binds in a reversible 
fashion to the adenosine triphosphate (ATP) binding site of the receptor. It is an inhibitor of 
epidermal growth factor receptor tyrosine kinase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4 Erlotinib 
 
Tetrodotoxin 
Tetrodotoxin Fig 5 (also known as "tetrodox" and frequently abbreviated as TTX, sometimes 
colloquially referred to as "zombie powder" by those who practice Vodou or are of Haitian 
descent) chemically known as (4R,4aR,5R,6S,7S,8S,8aR,10S,12S)-2-azaniumylidene-4,6,8,12-
tetrahydroxy-6-(hydroximethyl)-2,3,4,4a,5,6,7,8-octahydro-1H-8a,10-methano-5,7-
epoxymethanoxy)  quinazolin-10-olate (Rivera et al., 1995). It is a potent neurotoxin with no 
known antidote. There have been successful tests of a possible antidote in mice, but further tests 
must be carried out to determine efficacy in humans. Tetrodotoxin blocks action potentials in 
nerves by binding to the voltage-gated, fast sodium channels in nerve cell membranes, 
essentially preventing any affected nerve cells from firing by blocking the channels used in the 
process.  
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Fig 5 Tetrodotoxin 
 
 
Alfuzosin 
The trade name of alfuzosin Fig 6 are UroXatral; Urion; Xatral; Alfetim, chemically known as N-
[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]propyl] tetra- hydrofuran -2-
carboxamide (Hwang et al., 2007). It is a α1 receptor antagonist used to treat benign prostatic 
hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it 
easier to urinate. Alfuzosin should be used with caution in patients with severe renal 
insufficiency, and should not be prescribed to patients with a known history of QT prolongation 
who are taking medications known to prolong the QT interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6 Alfuzosin 
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Trimetrexate 
Trimetrexate Fig 7 chemically known as 5-methyl-6-[(3,4,5-trimethoxyphenyl) aminomethyl] 
quinazoline-2,4-diamine (Wong et al., 1990, Smith et al., 2002), is a nonclassical folic acid 
inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for 
efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis 
pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.  It has been 
used with leucovorin in treating pneumocystis pneumonia. It has been investigated for use in 
treating leiomyosarcoma.It is a methotrexate (MTX) analog that is active against transport-
deficient MTX-resistant tumor cells that overcome the acquired and natural resistance to 
methotrexate. Other uses include skin lymphoma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7  Trimetrexate 
 
 
Bunazosin 
Bunazosin Fig 8, trade name is andante, chemically known as 1-(4-(4-amino-6,7-
dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one, is an alpha-1 antagonist. Bunazosin 
was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in 
Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous 
outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also 
may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor 
antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin 
potentially could have the same effect but there has been no research to substantiate this as a 
risk for cataract surgery. 
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Fig 8 Bunazosin 
 
Vandetanib 
The trade name of Vandetanib is zactima, Fig 9 also known as ZD6474, has chemical name N-(4-
bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine, it is 
an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal 
growth factor receptor (EGFR).  It is a tyrosine kinase inhibitor. Drug has a third target: inhibits 
RET-tyrosine kinase activity, an important growth driver in certain types of thyroid cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 9 Vandetanib 
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Anagrelide 
Its trade name are Agrylin/Xagrid, Shire, anagrelide Fig 10, and chemical name is 6,7-dichloro-
1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one (Voglová et al., 2006, Petrides, 2006), is a drug 
used for the treatment of essential thrombocytosis (ET), or overproduction of blood platelets. It 
also has been used in the treatment of chronic myeloid leukemia. Anagrelide works by 
inhibiting the maturation of platelets from megakaryocytes. The exact mechanism of action is 
unclear, although it is known to be a phosphodiesterase inhibitor.  It is a potent (IC50 = 36nM) 
inhibitor of phosphodiesterase-II. It inhibits PDE-3 and phospholipase A2. According to a 2005 
Medical Research Council randomized trial, the combination of hydroxyurea with aspirin is 
superior to the combination of anagrelide and aspirin for the initial management of ET. The 
hydroxyurea arm had a lower likelihood of myelofibrosis, arterial thrombosis, and bleeding, but 
it had a slightly higher rate of venous thrombosis. 
 
 
 
 
 
 
 
 
 
 
 
Fig 10 Anagrelide 
 
Evodiamine 
Evodiamine Fig 11 is chemically known as 21-methyl-3,13,21-triazapentacyclo [11.8.0.02,10.04, 
9.015,20] henicosa-2(10),4,6,8,15,17,19-heptaen-14-one (Kobayashi, 2001, Wang, 2008). It is 
extracted from the Evodia spp family of plants which has been shown to reduce fat uptake in 
mouse studies. Its method is believed to be similar to capsaicin, but retains none of the "hot" 
taste. This chemical has been known to appear in some bodybuilding over the counter 
supplements, while neither its fat-burning benefits, nor its potential risks and side effects, have 
ever been established scientifically or empirically. Evodiamine raises your body's temperature 
and can inhibit the growth of certain cancer cells. It also manipulates your metabolism when 
combined with certain drugs and influences the secretion of catecholamines from your adrenal 
glands. 
 
 
 
 
 
 
 
 
 
 
Fig 11 Evodiamine 
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Proquazone 
Its trade name is Biarison Fig 12 is chemically known as 1-isopropyl-7-methyl-4-
phenylquinazolin-2(1H)-one. Proquazone is a non-steroidal anti-inflammatory drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 12  Proquazone 
 
 
Nolatrexed 
Nolatrexed Fig 13 has chemical name 2-Amino-6-methyl-5-(4-pyridylthio)-1H-quinazolin-4-one 
(Hughes, et al., 1999). Nolatrexed is a thymidylate synthase inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 13 Nolatrexed 
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Quinethazone 
Its brand name is Hydromox Fig 14 chemically known as 7-chloro-2-ethyl-4-oxo-1,2,3,4-
tetrahydroquinazoline-6-sulfonamide (Cohen, et al., 1960). Quinethazone is a thiazide diuretic 
used to treat hypertension. Common side effects include dizziness, dry mouth, nausea, and low 
potassium levels. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 14 Quinethazone 
 
 
Albaconazole 
Albaconazole (UR-9825) Fig 15 chemically known as 7-chloro-3-[(2R,3R)-3-(2,4-difluoro phenyl) 
-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]quinazolin-4-one, is a triazole antifungal. It has 
potential broad-spectrum antibacterial activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 15 Albaconazole 
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Febrifugine 
Febrifugine Fig 16 chemically known as 3-{3-[(2S,3R)-3-Hydroxypiperidin-2-yl]-2-oxo propyl} 
quinazolin-4(3H)-one (McLaughlin, et al., 2010) is a quinazolinone alkaloid first isolated from 
Chinese herb Dichroa febrifuga, but also found in the garden plant Hydrangea.  Febrifugine has 
antimalarial properties and the halogenated derivative halofuginone is used in veterinary 
medicine as a coccidiostat. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 16 Febrifugine 
 
Afloqualone 
Its brand name is Arofuto,Fig 17 chemically known as 6-amino- 2-(fluoromethyl)- 3-(2-methyl 
phenyl) quinazolin- 4-one (Ochiai, et al., 1982, Ishikawa, et al., 1994). It is an analogue of 
methaqualone developed in the 1980s in Japan. It has sedative and muscle relaxant effects, and 
has had some clinical use, although it causes photosensitization as a side effect which can cause 
skin problems such as dermatitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 17 Afloqualone 
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Fenquizone 
Its brand name is Idrolone, Fig 18 chemically known as 7-chloro-4-oxo-2-phenyl-1,2,3,4-
tetrahydroquinazoline-6-sulfonamide, is a diuretic, part of the class of low-ceiling sulfonamide 
diuretics. Fenquizone is used primarily in the treatment of treatment of oedema and 
hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 18  Fenquizone 
 
 
Linagliptin 
Its trade name is Ondero, Fig 19 chemically known as 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-
yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione (Wang, 
et al., 2008). It is a DPP-4 inhibitor developed by Boehringer Ingelheim undergoing research for 
type II diabetes. Results from a Phase III clinical trial of linagliptin showed that the drug can 
effectively reduce blood sugar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 19 Linagliptin 
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Quinazolinone  
It is also called as quinazolindiones, Fig 20 chemically known as Quinazolin-4(3H)-one (Chen, et 
al., 2006). Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and 
one of the carbons oxidized with keto oxygen. Quinazolinone is a heterocyclic chemical 
compound. There are two structural isomers, 2-quinazolinone and 4-quinazolinone, with the 4-
isomer being the more common. Quinazolinones are also a class of drugs which function as 
hypnotic/sedatives that contain a 4-quiazolinone core. Their use has also been proposed in the 
treatment of cancer. Examples include afloqualone, cloroqualone, and diproqualone. Alkaloids 
containing the quinzolinone core include febrifugine and halofuginone. 
 
 
 
 
 
 
 
 
 
 
Fig 20 Quinazolinone 
 
Quazinone  
Its brand name are dozonone, posicor Fig 21 chemically known as (3R)-6-chloro-3-methyl-5,10-
dihydroimidazo[2,1-b]quinazolin-2(3H)-one (Eigenmann, et al., 1984, Holck , et al., 1984, Belz, et 
al., 1985, Daly, et al., 1985, Osinski, et al., 2000, Denis et al., 1999), it is a cardiotonic  and  
vasodilator drug  which was developed and marketed in the 1980s for the treatment of heart 
disease.    It acts as a selective PDE3 inhibitor.  
 
 
 
 
 
 
 
 
 
Fig 21 Quazinone 
 
Quazodine 
Its brand name are quazodinum, quazodina Fig 22 chemically known as 4-ethyl-6,7-dimethoxy-
quinazoline (Amer, et al., 1971). The effects of quazodine and theophylline have been studied on 
the rat hemidiaphragm and chick biventer cervicis preparations in vitro. Theophylline and 
quazodine enhanced maximal twitches and contractural responses to acetylcholine and 
carbachol. These actions on contractility were exerted directly upon the muscle fibres and were 
dependent upon the concentration of calcium ions in the bathing solution. In addition, 
quazodine enhanced the neuromuscular blocking activity of tubocurarine, probably by a 
prejunctional action. 
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Fig 22 Quazodine 
 
Raltitrexed  
Its brand name is Tomudex, Fig 23 chemically known as N-[(5-{methyl[(2-methyl-4-oxo-1,4-
dihydroquinazolin-6-yl)methyl]amino}-2-thienyl)carbonyl]-L-glutamic acid, is an antimetabolite 
drug used in cancer chemotherapy. It is an inhibitor of thymidylate synthase, and is 
manufactured by AstraZeneca. Raltitrexed used in treatment of colorectal cancer since 1998. 
Raltitrexed is chemically similar to folic acid and is in the class of chemotherapy drugs called 
folate antimetabolites. It works by inhibiting Dihydrofolate reductase, an enzyme used in the 
synthesis of tetrahydrofolate, thereby preventing the synthesis of thymidylate. Raltitrexed is 
fully active after polyglutamylation. By inhibiting the formation of precursor pyrimidine 
nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the 
growth and survival of both normal cells and cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 23 Raltitrexed 
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Ketanserin 
It is Fig 24 chemically known as 3-[2-[4-(4-fluorobenzoyl) piperidin-1-yl]ethyl]-1H-quinazoline-
2,4-dione. It is a selective serotonin receptor antagonist with weak adrenergic receptor blocking 
properties. It inhibits platelet aggregation. It is well tolerated and is particularly effective in 
older patients. Drug is used in the treatment of acute or chronic vascular hypertension 
regardless of pharmacological mechanism. Drug binds to but do not activate serotonin 
receptors, thereby blocking the actions of serotonin, thus known as seretonin receptor 
antagonists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 24 Ketanserin 
 
 
Benzouracil 
Benzouracil Fig 25 is chemically known as 2,4(1H,3H)-quinazolinedione. The substituted 
Benzouracil used in treating or preventing an infection due to a virus from the Flaviridae family 
by administering to a patient in need there of an effective amount of a quinazoline derivative 
according to the structural formula. 
 
 
 
 
 
 
 
 
 
 
Fig 25 Benzouracil 
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CB 3717 
 CB 3717 Fig 26 chemically known as (2S)-2-[[4-[(2-amino-4-oxo-1H-quinazolin-6-yl)methyl-
prop-2-ynylamino] benzoyl]amino]pentanedioic acid. It is used as antineoplastic agent, folic 
acid antagonist of enzyme tetrahydrofolate dehydrogenase & used in cancer chemotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 26 CB 3717 
 
EBE-A22 
It is also known as PD 153035; PD-153035; PD153035; Fig 27 chemically known as N-(3-
bromophenyl)-6,7-dimethoxyquinazolin-4-amine (Cheng, et al., 2011). It is used as 
antineoplastic agent & intercalating agent (capable to insert themselves between bases of DNA). 
They are used in the study of DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 27 EBE-A22 
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NSC127213 
NSC127213 Fig 28 is chemically known as tetrazolo [1,5-c]quinazoline. NSC127213 is useful as 
inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, 
allergic, and ocular diseases. 
 
 
 
 
 
 
 
 
 
 
Fig 28 NSC127213 
 
NSC137192 
NSC137192 Fig 29 is chemically known as 8-methylbenzo[f]quinazoline-1,3-diamine. The drug 
invention provides compositions and methods for the treatment of B-cell proliferative disorders 
that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and 
compositions may further include an antiproliferative compound. 
 
 
 
 
 
 
 
 
 
 
 
Fig 29 NSC137192 
 
BIBN4096BS 
BIBN4096BS Fig 30 is chemically known as (R-(R*,S*))-N-(2-((5-amino-1-((4-(4-pyridinyl)-1-
piperazinyl)carbonyl)pentyl)amino)-1-((3,5-dibromo-4-hydroxyphenyl)methyl)-2-oxoethyl)-4-
(1,4-dihydro-2-oxo-3(2H)quinazolinyl)-1-piperidinecarboxamide (Mallee, et al., 2002, Doods, et 
al., 2000). It is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human 
temporal artery. Calcitonin gene-related peptide (CGRP) is one of the most potent endogenous 
vasodilators known. This peptide is increased during migraine attacks and has been implicated 
in the pathogenesis of migraine headache. Here we report on the first small molecule selective 
CGRP antagonist: BIBN4096BS. In vitro, this compound is extremely potent at primate CGRP 
receptors exhibiting an affinity (Ki) for human CGRP receptors of 14.4±6.3 (n=4) pM. In an in 
vivo model, BIBN4096BS in doses between 1 and 30µgkg−1 (i.v.) inhibited the effects of CGRP, 
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released by stimulation of the trigeminal ganglion, on facial blood flow in marmoset monkeys. 
It is concluded that BIBN4096BS is a potent and selective CGRP antagonist. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 30 BIBN4096BS 
 
ZD 9331 
It is also known as BGC9331, Fig 31 is chemically known as (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-
quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl) 
butanoic acid34. AstraZeneca (formerly Zeneca) is developing ZD-9331, a non-polyglutamatable 
thymidylate synthase inhibitor, as a potential treatment for solid tumors and other neoplasia, 
including colorectal tumors [216476,179954,179955]. ZD-9331 is being developed as both an oral 
and an i.v. formulation, both of which are in phase II trials as of December 1999 [349551,352095]. 
As of June 1998, ZD-9331 was in phase II trials for advanced colorectal and other solid tumors 
Br
HO
Br
O NH
NH
O
N
N
H
O
N
N
N
N
O
H2N
T Panneer Selvam & P Vijayaraj Kumar  /  Research in Pharmacy  1(1) : 1-21, 2011 
 
19 
 
[315489], with drug filings not expected until 2002 [349551]. A clinical study presented at the 
36th Annual Meeting of the American Society of Clinical Oncology (ASCO) demonstrated that 
treatment with ZD-9331 resulted in a period of intracellular 2'-deoxyuridine (dUrd) elevation, a 
surrogate marker of thymidylate synthase inhibition, with observed myelosuppression being no 
greater than that seen with raltitrexed and less than with bolus 5-FU [369475]. Results from a 56-
patient phase I study were presented at the 1999 ASCO meeting. Dose escalation followed a 
two-stage procedure. As in previous studies myelosuppression was the dose-limiting toxicity, 
occurring at 4.8 and 7.5 mg/m2/day, with one patient at each of these two doses experiencing a 
DLT. The MTD was not achieved until 12 to 16 mg/m2/day, based on which a fixed dose of 25 
mg/day was being evaluated [326935]. A number of other studies are ongoing, comparing once 
to twice daily dosages as well as the pharmacokinetics of the compound. Encouraging phase I 
data have been seen in melanoma, ovarian, colon and breast cancer; myelosuppression is the 
dose limiting toxicity in the majority of these studies [326938, 326943, 326945, 327399]. A phase I 
dose-escalation trial was conducted to evaluate the feasibility of a once 3-weekly 30-min i.v. 
infusion of ZD-9331, with doses ranging from 4.8 to 370 mg/m2. The regimen was overall well 
tolerated up to 370 mg/m2, with grade IV myelosuppression and grade IV diarrhea being 
observed in a small number of patients [288959, 377842]. In June 2000, Deutsche Bank predicted 
sales of $12 million in 2002 [374500]. In January 1999, ABN Amro predicted sales of US $8 
million in 2002 rising to $66 million in 2005 [316250, 328676]. In March 1999, Lehman Brothers 
predicted a 30% probability that the drug would reach the worldwide markets, and be launched 
in 2002 [336599]. 
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Conclusions 
The article has outlined the chemistry and biological activities of the quinazoline scaffold. The 
synthetic methodologies indicate the simplicity, maneuverability and versatility, which offer the 
medicinal chemist a complete range of novel derivatives. Given the advances in synthetic 
methodology and technology in recent years and the continued interest in the quinazoline 
skeleton in medicinal chemistry and drug development, the development of efficient and 
reliable methods for the construction of these molecules will ensure that this is an active and 
important area of research in heterocyclic chemistry. 
 
The high degree of protection against seizures can be positive signs for further 
investigation of quinazoline derivatives as anticonvulsants. The activity of quinazoline as 
antitubercular compounds in multi-drug resistant tuberculosis and their potent anthelmintic 
activity are promising. The broad spectrum antibacterial and antifungal activity of these 
compounds could lead to a new series of antimicrobials. The quinazoline derivatives have 
demonstrated significant antiviral and anticancer activities. The enzymes and receptor agonist 
or antagonist action of these derivatives furthers their biological importance. Thus quinazoline 
scaffold is not only synthetically important but also possesses a wide range of promising 
biological activities. Future investigations of this scaffold could give some more encouraging 
results. 
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